Pipeline

Pliant Therapeutics is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-β₁ signaling inhibition.

Program

Indication

Discovery

In Vitro In Vivo

Preclinical

Lead Op IND Enabling

Clinical

Phase I Phase II Phase III

Global Rights

PLN-74809

Dual selective inhibitor of a_Vβ₆/a_Vβ₁

Idiopathic Pulmonary Fibrosis

Stage of Development

Clinical - Phase II

PLN-74809

Dual selective inhibitor of a_Vβ₆/a_Vβ₁

Primary Sclerosing Cholangitis⁽¹⁾

Stage of Development

Preclinical - IND Enabling

PLN-1474

Selective inhibitor of a_Vβ₁

F3/F4 NASH – Associated Liver Fibrosis

Stage of Development

Preclinical - IND Enabling

Program 3

Anti-integrin mAb

Muscular Dystrophies

Stage of Development

Preclinical - Lead Op

Program 4

Undisclosed targets

Oncology

Stage of Development

Discovery - In Vivo

Early Stage

Undisclosed targets

Various

Stage of Development

Discovery - In Vitro

(1) We plan to submit an IND for PLN-74809 for the treatment of PSC in the first quarter of 2020 incorporating the data from the completed Phase 1a/1b healthy volunteer trial and plan to initiate a Phase 2a clinical trial for PSC thereafter.

Pliant’s lead program, PLN-74809, is a small-molecule, dual selective inhibitor of α_Vβ₁ / α_Vβ₆ for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). These integrins cause upstream activation of TGF-β₁ in actively fibrotic tissue. Inhibition of these integrins will block TGF-β₁ activation, thereby preventing the growth of fibrotic tissue within the lung and bile ducts. PLN-74809 is being evaluated in Phase 2a trials in patients with IPF.

Pliant’s second program, PLN-1474, is an oral, small-molecule, selective inhibitor of TGF-ß activation by the integrin α_Vβ₁ for the treatment of end-stage liver fibrosis in NASH. Clinical testing is anticipated to start in 2020.

Pliant has additional programs in IPF leveraging a tissue-specific approach to modulating TGF-β1 activation. Epithelial cells and fibroblasts have emerged as principal players in fibrosis pathophysiology. Our animal models confirm that selectively targeting TGF-β1 activation in these cells holds great therapeutic promise.

Pliant is also focused on developing small molecules to selectively target transcriptional regulation of epithelial-to-mesenchymal-transition (EMT), a process that is induced by TGF-β1. By selectively targeting EMT, Pliant aims to target many fibrotic diseases through novel mechanisms.